Viridian Therapeutics, Inc.\DE financials

VRDN CIK 0001590750

Source: EDGAR filings · Built 2026-06-02T04:20:04Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -276.89M -232.83M -185.07M -94.64M -54.92M -29.82M
EBITDA -362.94M -298.50M -253.93M -134.05M -79.61M -110.14M
Working Capital 823.54M 690.59M 459.84M 397.82M 186.53M 118.94M
Net Debt -837.74M -694.48M -455.36M -418.23M -195.28M -127.14M
Operating Margin -512.91% -99018.21% -81035.03% -7579.23% -2690.79% -10512.38%
Net Margin -483.56% -89387.09% -75711.46% -7329.23% -2680.16% -10544.29%
Return on Equity (ROE) -47.44% -40.19% -53.78% -32.87% -42.30% -92.23%
Return on Assets (ROA) -38.09% -36.36% -48.48% -29.85% -38.98% -84.35%
Current Ratio 12.65× 15.43× 18.26× 12.93× 14.68× 12.14×
Debt-to-Equity 0.05× 0.03× 0.05× 0.02× 0.01× 0.00×
Cash Conversion Ratio 0.81× 0.86× 0.77× 0.72× 0.69× 0.27×
Accruals Ratio -0.07× -0.05× -0.11× -0.08× -0.12× -0.62×
SBC % of Revenue 62.53% 13956.95% 21392.36% 1115.41% 488.19% 347.14%
CapEx Coverage -558.37× -454.64× -205.09× -117.74× -161.48× -709.02×
Free Cash Flow Per Share $-4.14 $-2.95 $-4.61 $-8.38

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 44.73× 5141.24× 3744.64× 680.90× 159.63× 66.29×
P/B 4.39× 2.31× 2.66× 3.05× 2.52× 0.58×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Selling, General and Administrative Expense 95.31M 61.08M 95.00M
Operating Expenses 434.24M 299.34M 254.76M 136.08M 82.69M 111.43M
Operating Income (Loss) -363.39M -299.04M -254.45M -134.30M -79.73M -110.38M
Income Tax Expense (Benefit) 0
Net Income (Loss) Attributable to Parent -342.60M -269.95M -237.73M -129.87M -79.41M -110.72M
Earnings Per Share, Basic $-5.31 $-4.05 $-6.66 $-31.13
Weighted Average Number of Shares Outstanding, Basic 44.76M 32.09M 11.92M 3.56M
Earnings Per Share, Diluted $-5.31 $-4.05 $-6.66 $-31.13
Weighted Average Number of Shares Outstanding, Diluted 44.76M 32.09M 11.92M 3.56M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Assets, Current 894.23M 738.46M 486.48M 431.17M 200.16M 129.61M
Assets 899.42M 742.40M 490.42M 435.09M 203.71M 131.25M
Long-term Debt 20.20M 4.64M 0
Liabilities, Current 70.70M 47.87M 26.64M 33.35M 13.64M 10.67M
Long-term Debt, Excluding Current Maturities 20.58M 20.20M
Liabilities 177.25M 70.76M 48.40M 40.03M 15.99M 11.22M
Stockholders' Equity Attributable to Parent 722.17M 671.64M 442.02M 395.06M 187.72M 120.04M
Common Stock, Shares, Outstanding 101.83M 80.99M 53.99M 41.31M 23.92M 4.23M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -276.39M -232.32M -184.17M -93.84M -54.58M -29.78M
Payments to Acquire Property, Plant, and Equipment 495.00K 511.00K 898.00K 797.00K 338.00K 42.00K
Net Cash Provided by (Used in) Investing Activities -37.56M -228.65M -94.25M -115.13M -74.29M -50.48M
Net Cash Provided by (Used in) Financing Activities 426.74M 457.74M 225.67M 322.24M 125.28M 101.31M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (VRDN CIK 0001590750), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

GPI

Group 1 Automotive, Inc

PTGX

PROTAGONIST THERAPEUTICS, INC.

APG

APi Group Corporation